Harvard Bioscience Inc (HBIO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $40.75M
Last updated: Nov 17, 2026 at 4:15 PM ET
Harvard Bioscience Inc (HBIO) Stock Chart
Harvard Bioscience (HBIO) has a latest price of $9.08 on Nov 17, 2026, 11.0% below its 52-week high of $10.20. Its price rose 37.7% over the past 12 months. The month-end price fell 62.9% over the 10 years through Oct 2026, a compound annual decline of 9.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $83.30 in Jun 2021 and its lowest $3.56 in Apr 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart HBIO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for HBIO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 28.2%, and over 6 months it rose 81.2%. The month-end price fell 79.7% over the 3 years through Oct 2026, a compound annual decline of 41.3%.
| Period | Change |
|---|---|
| 1 month | +12.2% |
| 3 months | +28.2% |
| 6 months | +81.2% |
| 12 months | +37.7% |
| 12 months, with dividends | +37.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -79.7% | -41.3% |
| 5 years | -88.2% | -34.8% |
| 10 years | -62.9% | -9.4% |
Price by Year
Its best calendar year was 2023, when the price rose 93.1%, and its weakest was 2025, when it fell 68.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $8.90 | +33.1% |
| 2025 | $6.69 | -68.3% |
| 2024 | $21.10 | -60.6% |
| 2023 | $53.50 | +93.1% |
| 2022 | $27.70 | -60.7% |
| 2021 | $70.50 | +64.3% |
| 2020 | $42.90 | +40.7% |
| 2019 | $30.50 | -4.1% |
| 2018 | $31.80 | -3.6% |
| 2017 | $33.00 | +8.2% |
Trading Range
The price is 8.3% above its 50-day average of $8.38 and 36.9% above its 200-day average of $6.63.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $9.08 | |
| 52-week high | $10.20 | -11.0% |
| 52-week low | $4.00 | +127.0% |
| 50-day average | $8.38 | +8.3% |
| 200-day average | $6.63 | +36.9% |
Price Risk
Over 3 years, its largest fall from a peak was 94.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.38 |
| Largest fall, 1 year | -45.2% |
| Largest fall, 3 years | -94.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About HBIO
What is HBIO's 1-year price change?
Harvard Bioscience's price rose 37.7% over the past 12 months. With dividends included, the 12-month total return was 37.7%.
What is HBIO's 5-year price change?
Harvard Bioscience's month-end price fell 88.2% over the 5 years through Oct 2026, a compound annual decline of 34.8%. These figures leave out dividends.
What is HBIO's 52-week high and low?
Harvard Bioscience's 52-week high is $10.20 and its 52-week low is $4.00. Its latest price of $9.08 on Nov 17, 2026 is 11.0% below the high.
What is HBIO's beta?
Harvard Bioscience's 1-year beta against the S&P 500 is 1.38, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 45.2%.
Is the HBIO chart free?
Yes. Advanced Charting for HBIO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
HBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts